NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ifinatamab deruxtecan at a 12 mg/kg dose in pretreated patients. This dose has been ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd ...

Daiichi Sankyo granted Merck exclusive, worldwide rights (excluding Japan) to co-develop and co-commercialize Daiichi's 3 antibody-drug conjugates (ADCs) including patritumab deruxtecan (HER3-DXd ...

The revenue for Datopotamab deruxtecan is expected to reach an annual total of $1.45 bn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is a prescription drug that’s used to treat certain cancers, such as breast cancer. Enhertu can cause side effects that range from mild to serious.

Enhertu (fam-trastuzumab deruxtecan-nxki) is a prescription drug that’s used to treat certain types of cancer. Enhertu’s cost may depend on factors such as your dosage, whether you have health ...

New changes to the UK's immigration laws, including substantial increases to visa fees and higher salary thresholds for applicants, are raising concern among cancer researchers and other stakeholders ...

Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase ...